Announcements Trials
Browse Landscape

Phase

Phase 2 71Phase 1 42Phase 3 33Phase NA 32Phase 1/2 24Phase EARLY_PHASE1 6Phase 4 6Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Breast Neoplasms 117Neoplasms 101Prostatic Neoplasms 76Carcinoma, Non-Small-Cell Lung 75Colorectal Neoplasms 73Carcinoma, Hepatocellular 67Leukemia, Myeloid, Acute 58Stomach Neoplasms 52Neoplasm Metastasis 50Lung Neoplasms 48Precursor Cell Lymphoblastic Leukemia-Lymphoma 44Pancreatic Neoplasms 40Recurrence 36Head and Neck Neoplasms 32Rectal Neoplasms 30Colonic Neoplasms 30Leukemia 29Multiple Myeloma 28Ovarian Neoplasms 26Lymphoma 25Squamous Cell Carcinoma of Head and Neck 24Hematologic Neoplasms 23Melanoma 22Urinary Bladder Neoplasms 20Liver Neoplasms 20Polycystic Ovary Syndrome 19Myelodysplastic Syndromes 19Lymphoma, Large B-Cell, Diffuse 19Esophageal Neoplasms 19Uterine Cervical Neoplasms 16

Interventions

venetoclax 1cedazuridine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Hematologic Diseases × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡